Dr. Duliege is a senior executive (Executive Vice President, Chief Medical Officer, Head of Research & Clinical Development) with over 25 years of experience in the pharmaceutical industry.
Dr. Duliege is currently the EVP and CMO of Rigel Pharmaceuticals, where she is leading the development of new drugs for auto-immune diseases. Prior to that, she was EVP, Chief of strategic Development and Head of Immuno-oncology at ChemoCentryx where she initiated a program in pancreatic cancer. Prior to ChemoCentryx, Dr. Duliege was first VP, then CMO and Head of Research at Affymax. Under Dr. Duliege’s leadership, her team completed an extensive development program and obtained FDA approval of the company’s lead product for anemia in dialysis patients. Prior to joining Affymax, Dr. Duliege was a Senior Medical Director at Chiron where she built a record of significant clinical accomplishments in executing Phase I through IV studies in pulmonary medicine, infectious diseases, and immunology. Before Chiron, Dr. Duliege was a Senior Research Physician at Genentech, working on HIV vaccine and treatment. Prior to her career in the pharmaceutical industry, Dr. Duliege was an Epidemiologist with the National Institute of Science and Medical Research in Paris.
Dr. Duliege received her M.D. degree and certification in Pediatrics from Paris Medical School, an M.S. in Epidemiology from Harvard School of Public Health, and an M.S. in Biostatistics also from Paris Medical School. She continues to practice medicine as an Adjunct Clinical Assistant Professor at Stanford School of Medicine and Lucile Packard Children’s Hospital. In 2012, she was appointed by the California State Controller to serve on the board of CIRM, the California Institute for Regenerative Medicine (stem cell research). She also serves on the boards of nonprofit organizations focused on causes such as the prevention of HIV or improving access to health care in developing countries.